Resources from the same session
1735 - Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)
Presenter: Enriqueta Felip
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
2521 - Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase 3 ALTA-1L trial
Presenter: Sanjay Popat
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
5074 - Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study
Presenter: Rafal Dziadziuszko
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
4315 - Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
Presenter: Benjamin Solomon
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
1727 - Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC ASCEND-8)
Presenter: Byoung Chul Cho
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
Poster Discussion session - NSCLC, metastatic 1 - Invited Discussant LBA57, LBA58, 1379PD, 1380PD and LBA59
Presenter: Pasi Janne
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Slides
Webcast
1458 - Uncommon EGFR mutations in lung adenocarcinomas: clinical features and response to tyrosine kinase inhibitors
Presenter: Aurélien Brindel
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
1404 - Gefitinib With or Without Pemetrexed in Nonsquamous (NS) Non–Small Cell Lung Cancer (NSCLC) With EGFR Mutation (mut): Final Overall Survival (OS) Results From a Randomized Phase II Study
Presenter: James Chih-Hsin Yang
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
2191 - Phase III Study of Gefitinib (G) versus Gefitinib+Carboplatin+Pemetrexed (GCP) as 1st-line Treatment for Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations (NEJ009)
Presenter: Masahiro Seike
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract
4823 - An open-label, multicenter, phase 1 study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)
Presenter: Ross Camidge
Session: Poster Discussion session - NSCLC, metastatic 1
Resources:
Abstract